Drug Database
Back to search

Canada· CA-DIN-02430347

ELOCTATE

A coagulation factor viii product containing antihemophilic factor (recombinant bdd), fc fusion protein, registered in Canada by SANOFI-AVENTIS CANADA INC. The same ATC class is registered in 11 of our 19 countries.

ATC B02BD02

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedELOCTATEATCB02BD02REGISTER NO.CA-DIN-02430347PACKS LISTED0CHECKEDOctober 1, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about antihemophilic factor (recombinant bdd), fc fusion proteinAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Coagulation factor viii is registered in 11 of 19 countries.

Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 7 of them publish a price we can compare per daily dose
Search coagulation factor viii products by name

Coagulation factor viii · ATC B02BD02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN
Manufacturer
SANOFI-AVENTIS CANADA INC
Country
Canada (CA)
ATC code
B02BD02
ATC class
Coagulation factor VIII
Defined daily dose
1 TSD, E
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

4 interactions on record for coagulation factor viii.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check coagulation factor viii against other medicinesHow interaction checks work

Coagulation factor viii · interactions on record

4 records

  • 2 severe
  • 2 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • PegvaliaseA16AB19moderate
  • EmicizumabB02BX06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Coagulation factor viii in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All coagulation factor viii products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Elocta
  • Liechtenstein · Elocta
  • Norway · Elocta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e617215b-9a8a-488d-ab9f-8289290629b2
GET /v1/drugs/e617215b-9a8a-488d-ab9f-8289290629b2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02430347",
  "form": "POWDER FOR SOLUTION",
  "class": "Human",
  "routes": [
    "INTRAVENOUS"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "B02BD02",
  "schedule": [
    "Schedule D"
  ],
  "drug_code": "91483",
  "strengths": [
    "2000 UNIT"
  ],
  "ahfs_class": null,
  "substances": [
    "ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN"
  ],
  "product_categorization": null
}
API referenceMCP serverPlans

See everything about coagulation factor viii.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console